Market Overview –

The market for fetal bovine serum was estimated to be worth USD 0.9 billion in 2022 and is expected to increase to USD 1.5 billion by 2030, with a compound annual growth rate (CAGR) of 5.7% from USD 0.95 billion in 2023 to USD 1.5 billion in 2023.

The fetal bovine serum (FBS) market involves the production, distribution, and sale of serum derived from the blood of fetal calves, primarily used as a growth medium supplement in cell culture applications. FBS contains essential nutrients, growth factors, and hormones necessary for cell growth and proliferation, making it indispensable in biomedical research, pharmaceutical development, and biotechnology industries.

One of the primary drivers of the FBS market is the growing demand for cell culture-based research and production activities in various fields, including drug discovery, vaccine development, regenerative medicine, and biologics manufacturing. FBS serves as a vital component in cell culture media formulations, supporting the growth of a wide range of cell types and facilitating the study of cellular processes and disease mechanisms.

The fetal bovine serum (FBS) market, with a spotlight on heat-inactivated FBS, is experiencing notable growth. Heat inactivation ensures sterility and safety, making it a preferred choice in cell culture applications. With expanding biomedical research and biopharmaceutical production, the demand for high-quality FBS, particularly heat-inactivated variants, is on the rise, driving market expansion.

Segmentation:

The global fetal bovine serum market, as in the report released by MRFR, has been segmented by application, product type, and end user. These segments hold various market dynamics and factors known for their influential contributions in furthering the market concerns. A deep look into these could reveal various pointers that can help companies in planning their moves.

By product type, the report on the fetal bovine serum market can be segmented into Charcoal Stripped, Dialyzed Fetal Bovine Serum (FBS), Chromatographic, Stem Cell, Exosome Depleted, and others. The stem cell segment has sub-segments like embryonic stem cells qualified, and mesenchymal stem cell qualified.

By application, the report discussing the fetal bovine serum market can be segmented into cell culture media, drug discovery, human & animal vaccine production, diagnostics, in-vitro fertilization, and others. The drug discovery segment would increase its intake due to the recent changes in market dynamics.

By end user, the report studies the market on the basis of pharmaceutical, biotechnology, research & academic institutes, and others. The pharmaceutical sector is expected to provide substantial market back up to the global market.

Regional Analysis:

The Americas has a chance to observe high growth in the market using which it would continue its domination. The regional market is slated to benefit from the presence of the US and Canada. These two countries are known for their extensive market contributions as their pharmaceutical sectors are providing various supports to the regional market. Europe would benefit from its extensive research and development facilities. Countries from the region would invest substantially in developing new drugs. In the Asia Pacific region, the inclusion of latest technologies in various sectors to boost industrial growth would ease the path for market percolation.

Key Players –

Fetal bovine serum companies include HiMedia Laboratories, Merck KGaA, Bovogen Biologicals Pty Ltd, Atlanta Biologicals Inc., TCS Biosciences Ltd, Tissue Culture Biologicals, Rocky Mountain Biologicals, GE Healthcare, Thermo Fisher Scientific, Bio-Techne, PAN-Biotech, and Access Biologicals.

Related Reports –

chronic kidney disease market

mental health software devices market

palliative care market

next generation sequencing market

For more information visit at MarketResearchFuture